Library

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.

1 September 2008. doid: 10.1007/s00432-008-0372-8

Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, Cohen AF, Burggraaf J

View publication

The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact